Solifenacin

• CAS: 180272-14-4
• Catalog Number: ACM180272144
• Category: Main Products
• Molecular Weight: 362.47
• Molecular Formula: C₂₃H₂₆N₂O₂
• IUPAC Name: 1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydro-1H-isoquinoline-2-c...
• Boiling Point: 505.5ºC at 760 mmHg
• Flash Point: 259.5ºC
• Density: 1.24 g/cm³
• Exact Mass: 362.19900

Case Study

Solifenacin for the Treatment of Overactive Bladder: A Comparative Clinical Evaluation with T-PTNS Therapy

Memmedova S, et al. Continence, 2024, 12, Supplement, 101513.

In a randomized controlled trial investigating therapeutic options for overactive bladder (OAB), solifenacin was evaluated alongside transcutaneous posterior tibial nerve stimulation (T-PTNS) to assess its clinical efficacy and impact on patient quality of life. Thirty-four female patients aged 18 to 80, all diagnosed with OAB, were assigned to receive either oral solifenacin or T-PTNS over a 6-week period.
The solifenacin group was administered 5 mg of the drug orally once daily throughout the treatment duration. Participants were monitored using a battery of validated urological and quality-of-life assessments, including OAB-V8, IIQ-7, UDI-6, and I-QOL questionnaires, in addition to detailed bladder diary recordings. Baseline and post-treatment scores were statistically analyzed using SPSS 20.0 software to evaluate intra-group and inter-group differences.
Results demonstrated that both treatment arms significantly improved OAB-related symptoms; however, patients treated with solifenacin reported notable reductions in urgency, frequency, nocturia, and incontinence episodes. Despite its effectiveness, solifenacin's long-term use is potentially limited by anticholinergic side effects, such as dry mouth, although no adverse events were recorded during this short-term study.This study underscores the utility of solifenacin as a pharmacological intervention in OAB management and highlights its comparative effectiveness when evaluated against non-invasive neuromodulation therapies like T-PTNS.

Solifenacin for the Treatment of Primary Monosymptomatic Nocturnal Enuresis: A Randomized Controlled Study

Ahmad T, et al. Journal of Pediatric Surgery, 2023, 58, 2034-2037.

In this randomized controlled trial, the therapeutic efficacy of Solifenacin in combination with desmopressin was evaluated for the treatment of primary monosymptomatic nocturnal enuresis (PMNE) in pediatric patients. A total of 88 children, aged 5-14 years, were enrolled and randomized into two groups. Group 1 received monotherapy with one puff of desmopressin nasal spray administered nightly, one hour before bedtime. Group 2 received combination therapy comprising one 5 mg oral tablet of Solifenacin along with desmopressin nasal spray at the same dosage and schedule.
Following a three-month treatment period, therapeutic response and adverse effects were assessed. The complete response rate in the combination group (84.09%) was significantly higher than in the desmopressin-only group (61.36%) (p < 0.05). Although side effects were slightly more common in the combination group (27.27% vs. 18.18%), the difference was not statistically significant, and no treatment discontinuations occurred. Notably, the recurrence rate was substantially lower in the combination group (8.1% vs. 33.3%, p < 0.05). This study demonstrates the effective experimental application of Solifenacin in combination therapy for PMNE, supporting its role in enhancing therapeutic outcomes when paired with desmopressin.

Custom Q&A

What is the molecular formula of Solifenacin?

The molecular formula of Solifenacin is C23H26N2O2.

What is the molecular weight of Solifenacin?

The molecular weight of Solifenacin is 362.5 g/mol.

What is the synonym for Solifenacin?

The synonym for Solifenacin is Soliten.

What is the pharmacological classification of Solifenacin?

Solifenacin is classified as a Cholinergic Muscarinic Antagonist.

What is the mechanism of action of Solifenacin?

The mechanism of action of Solifenacin is as a Cholinergic Muscarinic Antagonist.

How often is Solifenacin usually taken?

Solifenacin is usually taken once daily.

When was Solifenacin granted FDA approval?

Solifenacin was granted FDA approval on 19 November 2004.

What is the IUPAC name of Solifenacin?

The IUPAC name of Solifenacin is [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate.

What is the InChIKey of Solifenacin?

The InChIKey of Solifenacin is FBOUYBDGKBSUES-VXKWHMMOSA-N.

What is the CAS number for Solifenacin?

The CAS number for Solifenacin is 242478-37-1.